The situation of the global pandemic is grim. Currently, clinical trials are evaluating monoclonal antibodies (mAbs) for the prevention or treatment of COVID-19. The following research reported on mAb therapy for COVID-19 in high-risk patients[1]. mAbs bind to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike(S) protein and block viral entry into host cells, neutralizing the virus.

Between November 2020 and February 2021, 4 therapeutic mAbs have been authorized by the US Food and Drug Administration (FDA) and given Emergency Use Authorization (EUA). These therapeutic mAbs are being used for treatment of patients with mild to moderate COVID-19 within 10 days of symptom onset: 700mg bamlanivimab, 1400mg etesevimab, 1200mg casirivimab, and 1200mg imdevimab. However, data is limited, and the role of mAbs in patients with COVID-19 remains controversial. J. Ryan has conducted a research on this issue. He quantifies the risk-adjusted association between bamlanivimab monotherapy treatment and no bamlanivimab treatment on hospitalizations, mortality, and emergency department (ED) visits among outpatients at high risk of progressing to severe COVID-19. The results indicate that bamlanivimab monotherapy was associated with reduced hospitalizations and mortality within 28 days among patients with mild to moderate COVID-19. In the propensity-matched analyses, patients receiving bamlanivimab had an estimated 60% lower risk adjusted odds of hospitalization or mortality (OR, 0.40; 95% CI, 0.24 to 0.69) and estimated 46% lower risk-adjusted odds of hospitalization or ED visit without hospitalization (OR, 0.54; 95% CI, 0.35 to 0.82) (Table 1).

Table 1 . Primary and Secondary Outcomes From Propensity-Matched Models Stratified by Age

In the general population, mAb treatment decreased the risk of hospitalization and death by 60%[2], Overall, mAbs are a promising therapy technique. Synbio Technologies has a robust antibody drug discovery platform utilized by our talented scientific team from both local and international antibody specialists. This platform provides a full range of services in custom monoclonal antibody production including immunization, hybridoma development, antibody discovery, antibody functional screening assays, antibody engineering, and antibody expression. Using this platform, we can deliver up to 10 high-quality functional hybridoma clones to jumpstart our customers’ antibody research.

Competitive Advantages


Proprietary Immunization Technology: Compared to traditional immunogen design, our Universal AntigenTM technology can induce antibodies to recognize epitopes containing less than 5 amino acids.
One Stop Solution: Streamlined strategy from immunization to hybridoma generation and characterization.
Reliable High-Throughput Screening Assays: Optimized immunization and high-throughput screening for affinity measurements, epitope binning, isotyping, etc.
Comprehensive Functional Assay: Extensive experience in antibody affinity ranking, affinity measurement, cross-reactivity, and other in-vitro biological analysis.

Related Services


1. Ganesh R, Philpot LM, Bierle DM, et al. Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab among High-Risk Patients with Mild to Moderate Coronavirus Disease 2019. J Infect Dis 2021
2. Bariola JR, McCreary EK, Wadas RJ, et al. Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection. Open Forum Infectious Diseases 2021